About VAHO
Founded in 1990, the Virginia Association of Hematologists and Oncologists (VAHO) is the largest oncology professional organization in the state. VAHO comprises a powerful community of oncologists, nurse practitioners, physician assistants, pharmacists, and other multidisciplinary care providers involved in the treatment of patients with cancer.
Events Calendar view all
2026 Spring MeetingThu |
Industry News view all
12/11/2025Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025Highlights include updates from the company’s targeted protein degradation pipeline, including data on first-in-class investigational lymphoma CELMoD™ agent golcadomide and first-in-class BCL6 ligand-directed degrader BMS-986458; alongside long-term results for Breyanzi® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, from the Phase 3 TRANSFORM and Phase 2 TRANSCEND FL trials. “The data presented at ASH represent a significant step forward in our pursuit of transformative outcomes for patients with lymphoma, who urgently need more effective and durable treatment options,” said Anne Kerber, senior vice president, head of development, Hematology, Oncology and Cell Therapy, Bristol Myers Squibb. “From the potential of golcadomide to offer meaningful benefit in aggressive B-cell and follicular lymphomas, to the innovative mechanism of our BCL6 ligand-directed degrader, BMS-986458, and the proven, long-term efficacy of Breyanzi – these collective results underscore our dedication to pioneering therapies that make a real difference for patients.” |
11/21/2025FDA approves (Zepzelca) lurbinectedin in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs for extensive-stage small cell lung cancerOn October 2, 2025, the Food and Drug Administration approved lurbinectedin (Zepzelca, Jazz Pharmaceuticals, Inc.) in combination with atezolizumab (Tecentriq, Genentech Inc.) or atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech Inc.) for the maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy with atezolizumab or atezolizumab and hyaluronidase-tqjs, carboplatin, and etoposide. Full prescribing information for Zepzelca, Tecentriq, and Tecentriq Hybreza will be posted on Drugs@FDA. |
11/21/2025FDA approves (LIBTAYO) cemiplimab-rwlc for adjuvant treatment of cutaneous squamous cell carcinomaOn October 8, 2025, the Food and Drug Administration approved cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals Inc.) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation. Second FDA approval for TEVIMBRA in 2024 |
